Basel, June 17, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment ...
Approval was supported by adult HS and psoriasis clinical trials, pharmacokinetic modeling, and data from established pediatric indications. The Food and Drug Administration (FDA) has approved ...
Novartis has secured the Food and Drug Administration’s blessing for Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis in four years and older, and active juvenile ...
EAST HANOVER, N.J., Jan. 15, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for two new indications - the treatment ...
Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...
Please provide your email address to receive an email when new articles are posted on . This approval makes Cosentyx the first interleukin-17A inhibitor and second biologic approved for hidradenitis ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cosentyx may soon share the hidradenitis suppurativa (HS) field with another inflammatory biologic—but, for now, the Novartis drug has a head start. That’s good news for the Swiss Pharma, given that ...
Novartis NVS announced that the FDA has approved a label expansion of IL-17 inhibitor, Cosentyx (secukinumab). Cosentyx is now approved for the treatment of active non-radiographic axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results